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Introduction
The prevalence of autoimmune hepatitis (AIH) is 160 to 170 per 1 000 000 population in Europe, with women being more frequently affected. 1 According to the International Autoimmune Hepatitis Group (IAIHG) scoring system last revised in 2015, AIH is diagnosed on the basis of biochemical and serological tests along with histologic examination of the liver.
1,2 Optimal therapy is challenging when AIH is accompanied by chronic hepatitis C, as these 2 conditions require different therapeutic strategies. Until 2014, the only available antiviral therapy was interferon alfa, associated with the risk of exacerbation of autoimmune diseases. On the other hand, immunosuppressive treatment could enhance viral replication. The new interferon -free regimens with direct -acting antiviral agents (DAAs) are promising for this difficult -to -treat population.
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In 2015, an estimated 71 million people suffered from chronic hepatitis C virus (HCV) infection, with the highest reported prevalence in the Eastern Mediterranean Region and European Region according to the World Health Organization.
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The prevalence of HCV infection with concomitant AIH remains unknown. New effective therapies are now broadly available; however, data regarding the safety and efficacy of DAAs in these patients are limited.
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Prednisone monotherapy was introduced, followed by addition of azathioprine as AIH reactivation was suspected (12 points in the IAI-HG scoring system). Biochemical recovery was achieved within 6 weeks. No liver decompensation or HCV infection reactivation was observed at 2 years. Two patients (No. 2 and 3) treated with budesonide developed exogenous Cushing syndrome with moderate clinical manifestation in the first 2 weeks of 3D treatment despite a reduction in glucocorticoid dose according to the patient information leaflet. Symptoms subsided after further glucocorticoid dose reduction. Both patients continued with modified treatment, and patient No. 3 permanently stopped immunosuppressive therapy at 48 weeks, with no further hepatitis flare.
Patient No. 4 did not start immunosuppressive therapy, although its implementation was considered before antiviral treatment. The reason was normalization of AIH activity after HCV eradication.
We observed some fluctuations in autoimmune marker levels, with an inconclusive decrease of γ -globulins and immunoglobulin G levels in most patients and the appearance of previously absent antibodies. Additional data are provided in Supplementary material, Table S1 . Discussion The choice of optimal therapy strategy in chronic HCV infection and comorbid autoimmune liver disorders is challenging. New highly effective interferon -free regimens allow a rapid HCV elimination in this population of patients. 3, 6 Apart from the previously reported good virological and biochemical response, we observed a decrease of liver stiffness on SWE. The impact of sustained viral response on liver stiffness was reported in patients treated with immunomodulating interferon -based regimens.
7 As there is no evidence for the direct anti -inflammatory effect of DAAs, our results suggest the absence of HCV replication as the cause of sustained fibrosis regression. However, it is important to note that necroinflammatory hepatic activity in AIH might also have influenced liver stiffness in SWE assessment.
Drug-drug interactions are one of the important negative aspects of DAA therapy. We observed moderate exogenous Cushing syndrome in the patient treated with budesonide. Such interactions were previously observed because CY-P3A4 inhibitors may repeatedly increase the systemic availability of budesonide. 8 Contemporary next -generation DAAs allow the use of regimens without strong CYP3A4 inhibitors.
The most important clinical finding of our study is the impact of effective DAA therapy on the course of AIH. In one patient, immunosuppressive therapy was withdrawn after HCV elimination. On the other hand, one patient experienced the biochemical and clinical manifestation of hepatitis flare with an exacerbation of
Adverse events and laboratory abnormalities that occurred during treatment and at 24 -week follow -up were evaluated according to common toxicity criteria (Common Terminology Criteria for Adverse Events version 4.0 by the National Cancer Institute of the National Institutes of Health). HCV RNA was measured by real--time polymerase chain reaction using the GeneProof Hepatitis C PCR Kit (GeneProof a.s., Brno, Czech Republic) and performed on a Rotor -Gene 3000 (Corbett Research, Australia; sensitivity (limit of detection), 7.87-208.544 IU/ml; linear range, 10 10 -25 IU/ml ±0.5log). The immune activity of AIH was assessed at baseline, end of treatment, and at 24 -week and 2 -year follow -up, using serum protein electrophoresis test (Capillarys Protein(e) 6, CAPILLARYS 2, Sebia, France), the measurement of immunoglobulin M and G levels (COBAS 6000 Modular biochemistry analyzer, Roche, city, Germany), and the measurement of antinuclear, anti-smooth muscle, antimitochondrial, and liver -kidney microsomal type 1 antibodies (indirect immunofluorescence method; Mosaic Basic Profil 1, EUROIMMUNE, Lubeck, Germany; a fluorescence microscope with a ×40 objective), with the titer calculated based on the dilution factor.
Liver fibrosis was evaluated at baseline and at 24 -week and 2 -year follow -up, with real -time shear -wave elastography (SWE), using the Aixplorer US system (SuperSonic Imagine S.A., Aix--en -Provence, France) with a convex broadband probe (SC6 -1). Liver stiffness was measured in 5 different circular regions of interest in the right lobe of the liver, through intercostal spaces performed by an experienced radiologist. Tissue elasticity was expressed in kilopascals (kPa), and the corresponding METAVIR score was calculated according to the cutoff values of SWE validated for hepatitis C.
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The study was conducted in accordance with the Declaration of Helsinki for Human Research, and the protocol was accepted by the local Bioethics Committees of the Medical Chamber (1/ BO/2014). All patients provided written informed consent prior to inclusion in the study.
Results All patients achieved sustained viral response with negative HCV RNA at 2 years, and showed persistent decline in α -fetoprotein levels and liver stiffness (TABLE 1) .
Patient No. 1 presented with ulcerative colitis exacerbation and hepatitis flare with elevated liver enzyme activity (aminotransferases 5 times the upper limit of normal), increased immunoglobulin G levels, and the presence of anti-smooth muscle antibodies (previously negative) at 9 weeks of follow-up. Due to liver cirrhosis and low platelet count, liver biopsy was not performed because it is a high -risk procedure.
